ATE396719T1 - Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose - Google Patents
Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen skleroseInfo
- Publication number
- ATE396719T1 ATE396719T1 AT02763962T AT02763962T ATE396719T1 AT E396719 T1 ATE396719 T1 AT E396719T1 AT 02763962 T AT02763962 T AT 02763962T AT 02763962 T AT02763962 T AT 02763962T AT E396719 T1 ATE396719 T1 AT E396719T1
- Authority
- AT
- Austria
- Prior art keywords
- multiplate
- trifluoromethylphenyl
- sclerosis
- cyano
- amide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28168501P | 2001-04-05 | 2001-04-05 | |
GBGB0123571.2A GB0123571D0 (en) | 2001-04-05 | 2001-10-02 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE396719T1 true ATE396719T1 (de) | 2008-06-15 |
Family
ID=26246599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02763962T ATE396719T1 (de) | 2001-04-05 | 2002-04-04 | Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1381356B1 (de) |
AR (1) | AR033459A1 (de) |
AT (1) | ATE396719T1 (de) |
CA (1) | CA2443285C (de) |
CY (1) | CY2014004I2 (de) |
DE (1) | DE60226855D1 (de) |
DK (1) | DK1381356T3 (de) |
ES (1) | ES2305287T3 (de) |
FR (1) | FR14C0010I2 (de) |
LU (1) | LU92366I2 (de) |
PA (1) | PA8542901A1 (de) |
PT (1) | PT1381356E (de) |
SI (1) | SI1381356T1 (de) |
UY (1) | UY27244A1 (de) |
WO (1) | WO2002080897A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003293500A1 (en) | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
SG142305A1 (en) * | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
JP5021488B2 (ja) | 2004-12-21 | 2012-09-05 | メルク セローノ ソシエテ アノニム | スルホニルアミノ環式誘導体及びその使用 |
DK1844032T3 (da) | 2005-01-31 | 2011-10-24 | Merck Serono Sa | N-hydroxyamid-derivater og deres anvendelse |
CA2616479A1 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
EP2100881A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Pyrimidinyl- oder Pyridinylaminobenzoesäurederivate |
EP2135610A1 (de) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Kombination mit DHODH-Inhibitoren und Methotrexat |
EP2230232A1 (de) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Zusatzsalze von Tromethamin mit Azebiphenylaminobenzoesäurederivate als DHODH-Inhibitoren |
EP2239256A1 (de) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Natriumsalz von 5-cyclopropyl-2-{[2-(2,6-difluorphenyl)pyrimidin-5-yl]amino}benzoesäure als DHODH-Inhibitor |
EP2228367A1 (de) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Zusatzsalze von Aminen mit Hydroxyl- und/oder Carboxylgruppen mit Aminonicotinsäurederivaten als DHODH-Inhibitoren |
EP2277515A1 (de) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Verwendung der Kombination aus Teriflunomid und Interferon beta zur Behandlung der multiplen Sklerose |
MX336663B (es) | 2009-09-18 | 2016-01-27 | Sanofi Sa | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada. |
EP2314577A1 (de) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Verfahren zur Herstellung von 2-[(3,5-Difluor-3'-methoxy-1,1'-biphenyl-4-yl)amino]nikotinsäure |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
US20140031383A1 (en) | 2011-02-08 | 2014-01-30 | Dana-Farber Cancer Institute, Inc. | Methods for treatment of melanoma |
EP2762135A1 (de) * | 2013-02-04 | 2014-08-06 | Sanofi | Verfahren zur Verringerung des Risikos auf einer schädlichen Teriflunomid- und Rosuvastatininteraktion bei Patienten mit Multipler Sklerose |
WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
GR1010137B (el) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES448386A1 (es) | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
TW314467B (de) | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
-
2002
- 2002-04-04 AT AT02763962T patent/ATE396719T1/de active
- 2002-04-04 EP EP02763962A patent/EP1381356B1/de not_active Expired - Lifetime
- 2002-04-04 ES ES02763962T patent/ES2305287T3/es not_active Expired - Lifetime
- 2002-04-04 PT PT02763962T patent/PT1381356E/pt unknown
- 2002-04-04 SI SI200230727T patent/SI1381356T1/sl unknown
- 2002-04-04 DE DE60226855T patent/DE60226855D1/de not_active Expired - Lifetime
- 2002-04-04 EP EP08004647A patent/EP1935416A3/de not_active Ceased
- 2002-04-04 DK DK02763962T patent/DK1381356T3/da active
- 2002-04-04 WO PCT/US2002/010773 patent/WO2002080897A1/en not_active Application Discontinuation
- 2002-04-04 AR ARP020101245A patent/AR033459A1/es not_active Application Discontinuation
- 2002-04-04 CA CA002443285A patent/CA2443285C/en not_active Expired - Fee Related
- 2002-04-05 PA PA20028542901A patent/PA8542901A1/es unknown
- 2002-04-05 UY UY27244A patent/UY27244A1/es unknown
-
2014
- 2014-01-23 CY CY2014004C patent/CY2014004I2/el unknown
- 2014-01-29 LU LU92366C patent/LU92366I2/fr unknown
- 2014-02-05 FR FR14C0010C patent/FR14C0010I2/fr active Active
Also Published As
Publication number | Publication date |
---|---|
WO2002080897A1 (en) | 2002-10-17 |
DE60226855D1 (de) | 2008-07-10 |
LU92366I2 (fr) | 2014-03-31 |
PT1381356E (pt) | 2008-07-24 |
FR14C0010I2 (fr) | 2014-11-21 |
EP1381356A1 (de) | 2004-01-21 |
AR033459A1 (es) | 2003-12-17 |
UY27244A1 (es) | 2002-07-31 |
SI1381356T1 (sl) | 2008-12-31 |
EP1935416A2 (de) | 2008-06-25 |
FR14C0010I1 (de) | 2014-03-14 |
PA8542901A1 (es) | 2003-11-12 |
CA2443285C (en) | 2007-08-21 |
CY2014004I1 (el) | 2015-12-09 |
EP1381356B1 (de) | 2008-05-28 |
EP1935416A3 (de) | 2008-10-22 |
DK1381356T3 (da) | 2008-09-22 |
ES2305287T3 (es) | 2008-11-01 |
CA2443285A1 (en) | 2002-10-17 |
CY2014004I2 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE396719T1 (de) | Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose | |
ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
ATE297917T1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
DE50212455D1 (de) | Verwendung von Dimerdiolen | |
ATE401309T1 (de) | Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen | |
DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
DE60021903D1 (de) | Verwendung von zusammensetzungen zur textilpflege | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
GB0123571D0 (en) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis | |
DE60211632D1 (de) | Verwendung von Cyclotetrasaccharide zur Erhöhung der "Aktiven-Sauerstoff-Eliminierenden-Aktivität" | |
DE60214355D1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
DE50205766D1 (de) | Verfahren zur herstellung von 2-halogenpyridincarbonsäureamiden | |
ATE311898T1 (de) | Zusammensetzungen zur entfernung von menschlichem cerumen | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
DE69931487D1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
DE60026644D1 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
DE60120990D1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
DE60041365D1 (de) | Verwendung von Riluzol zur Behandlung Multipler Sklerose | |
ATE251167T1 (de) | Oxazinocarbazole zur behandlung von cns- erkrankungen | |
ATE282609T1 (de) | Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl) (1,4)diazepan-1-yl)-2- (aryl)butyl)benzamide zur behandlung von allergischen krankheiten | |
ATE329915T1 (de) | Pyrrolderivate zur behandlung von durch cytokine vermittelte krankheiten | |
ATE273013T1 (de) | Verwendung von simethicone zur behandlung der ulzerativen kolitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1381356 Country of ref document: EP |